Search: onr:"swepub:oai:DiVA.org:oru-61451" >
Intradermal HIV-1 D...
Intradermal HIV-1 DNA immunization using needle-free ZetajetTM injection followed by HIV-modified vaccinia virus Ankara vaccination is safe and immunogenic in Mozambican young adults : a phase I randomized controlled trial
-
- Viegas, Edna Omar (author)
- Instituto Nacional de Saúde, Maputo, Mozambique; Division of Clinical Microbiology, Department of Laboratory Medicine, Huddinge, Karolinska Institutet, Sweden; Universidade Eduardo Mondlane, Maputo, Mozambique
-
- Tembe, Nelson (author)
- Instituto Nacional de Saúde, Maputo, Mozambique; Division of Clinical Microbiology, Department of Laboratory Medicine, Huddinge, Karolinska Institutet, Sweden; Universidade Eduardo Mondlane, Maputo, Mozambique
-
- Nilsson, Charlotta (author)
- Karolinska Institutet
-
show more...
-
- Meggi, Bindiya (author)
- Instituto Nacional de Saúde, Maputo, Mozambique
-
- Maueia, Cremildo (author)
- Instituto Nacional de Saúde, Maputo, Mozambique
-
- Augusto, Orvalho (author)
- Universidade Eduardo Mondlane, Maputo, Mozambique
-
- Stout, Richard (author)
- Bioject Medical Technologies Inc, Tualatin OR, United States
-
- Scarlatti, Gabriella (author)
- Institute for Research and Health Care (IRCCS), San Raffaele Scientific Institute, Milan, Italy
-
- Ferrari, Guido (author)
- Department of Surgery and Molecular Genetics and Microbiology, Duke University Medical Center, Durham NC, United States
-
- Earl, Patricia (author)
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAD)/National Institutes of Health (NIH), Bethesda MD, United States
-
- Wahren, Britta (author)
- Karolinska Institutet
-
- Andersson, Sören, 1957- (author)
- Örebro universitet,Institutionen för medicinska vetenskaper,Department of Laboratory Medicine, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden
-
- Robb, Merlin (author)
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, The Military HIV Research Program, Walter Reed Army Institute of Research, Bethesda MD, United States
-
- Osman, Nafissa (author)
- Universidade Eduardo Mondlane, Maputo, Mozambique
-
- Biberfeld, Gunnel (author)
- Karolinska Institutet
-
- Jani, Ilesh (author)
- Instituto Nacional de Saúde, Maputo, Mozambique
-
- Sandström, Eric (author)
- Microbiology,Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
-
show less...
-
(creator_code:org_t)
- Mary Ann Liebert, 2018
- 2018
- English.
-
In: AIDS Research and Human Retroviruses. - : Mary Ann Liebert. - 0889-2229 .- 1931-8405. ; 34:2, s. 193-205
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- We assessed safety and immunogenicity of HIV-DNA priming using ZetajetTM, a needle-free device intradermally followed by intramuscular HIV-MVA boosts, in 24 healthy Mozambicans. Volunteers were randomized to receive three immunizations of 600 µg (n = 10; 2 x 0.1mL) or 1200 µg (n = 10; 2 x 0.2mL) of HIV-DNA (3 mg/mL), followed by two boosts of 108pfu HIV-MVA. Four subjects received placebo saline injections. Vaccines and injections were safe and well tolerated with no difference between the two priming groups. After three HIV-DNA immunizations, IFN-γ ELISpot responses to Gag were detected in 9/17 (53%) vaccinees, while none responded to Env. After the first HIV-MVA, the overall response rate to Gag and/or Env increased to 14/15 (93%); 14/15 (93%) to Gag and 13/15 (87%) to Env. There were no significant differences between the immunization groups in frequency of response to Gag and Env or magnitude of Gag responses. Env responses were significantly higher in the higher-dose group (median 420 vs 157.5 SFC/million PBMC, p=0.014). HIV-specific antibodies to subtype C gp140 and subtype B gp160 were elicited in all vaccinees after the second HIV-MVA, without differences in titers between the groups. Neutralizing antibody responses were not detected. Two (13%) of 16 vaccinees, one in each of the priming groups, exhibited antibodies mediating antibody-dependent cellular cytotoxicity to CRF01_AE. In conclusion, HIV-DNA vaccine delivered intradermally in volumes of 0.1-0.2 mL using ZetajetTM was safe and well tolerated. Priming with the 1200 µg dose of HIV-DNA generated higher magnitudes of ELISpot responses to Env.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Keyword
- HIV
- vaccine
- Mozambique
- HIV-DNA
- HIV-MVA
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Viegas, Edna Oma ...
-
Tembe, Nelson
-
Nilsson, Charlot ...
-
Meggi, Bindiya
-
Maueia, Cremildo
-
Augusto, Orvalho
-
show more...
-
Stout, Richard
-
Scarlatti, Gabri ...
-
Ferrari, Guido
-
Earl, Patricia
-
Wahren, Britta
-
Andersson, Sören ...
-
Robb, Merlin
-
Osman, Nafissa
-
Biberfeld, Gunne ...
-
Jani, Ilesh
-
Sandström, Eric
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Infectious Medic ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Immunology in th ...
- Articles in the publication
-
AIDS Research an ...
- By the university
-
Örebro University
-
Karolinska Institutet